NATURE’S SUNSHINE PRODUCTS, INC. Accounts Receivable, Allowance for Credit Loss, Current
NATURE’S SUNSHINE PRODUCTS, INC. (NATR) had Accounts Receivable, Allowance for Credit Loss, Current of $61.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Current › Accounts Receivable, after Allowance for Credit Loss, Current
us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent · last filed 2026-08-06
- 2026-06-30: Accounts Receivable, Allowance for Credit Loss, Current $61.00K.
- 2026-03-31: Accounts Receivable, Allowance for Credit Loss, Current $63.00K.
- 2025-12-31: Accounts Receivable, Allowance for Credit Loss, Current $69.00K.
- 2025-09-30: Accounts Receivable, Allowance for Credit Loss, Current $66.00K.
| Period end | Accounts Receivable, Allowance for Credit Loss, Current |
|---|---|
| 2026-06-30 | $61.00K 10-Q · filed 2026-08-06 |
| 2026-03-31 | $63.00K 10-Q · filed 2026-05-07 |
| 2025-12-31 | $69.00K 10-Q · filed 2026-08-06 |
| 2025-09-30 | $66.00K 10-Q · filed 2025-11-06 |
| 2025-06-30 | $93.00K 10-Q · filed 2025-07-31 |
| 2025-03-31 | $91.00K 10-Q · filed 2025-05-06 |
| 2024-12-31 | $97.00K 10-K · filed 2026-03-10 |
| 2024-09-30 | $86.00K 10-Q · filed 2024-11-07 |
| 2024-06-30 | $138.00K 10-Q · filed 2024-08-08 |
| 2024-03-31 | $138.00K 10-Q · filed 2024-05-07 |
| 2023-12-31 | $142.00K 10-K · filed 2025-03-11 |
| 2023-09-30 | $154.00K 10-Q · filed 2023-11-07 |
| 2023-06-30 | $207.00K 10-Q · filed 2023-08-09 |
| 2023-03-31 | $122.00K 10-Q · filed 2023-05-09 |
| 2022-12-31 | $120.00K 10-K · filed 2024-03-12 |
| 2022-09-30 | $673.00K 10-Q · filed 2022-11-03 |
| 2022-06-30 | $525.00K 10-Q · filed 2022-08-09 |
| 2022-03-31 | $148.00K 10-Q · filed 2022-05-05 |
| 2021-12-31 | $143.00K 10-K · filed 2023-03-16 |
| 2021-09-30 | $445.00K 10-Q · filed 2021-11-04 |
| 2021-06-30 | $446.00K 10-Q · filed 2021-08-05 |
| 2021-03-31 | $451.00K 10-Q · filed 2021-05-06 |
| 2020-12-31 | $454.00K 10-K · filed 2022-03-08 |
| 2020-09-30 | $494.00K 10-Q · filed 2020-11-09 |
| 2020-06-30 | $423.00K 10-Q · filed 2020-08-06 |
| 2020-03-31 | $423.00K 10-Q · filed 2020-05-11 |
| 2019-12-31 | $407.00K 10-K · filed 2021-03-10 |
| 2019-09-30 | $405.00K 10-Q · filed 2019-11-07 |
| 2019-06-30 | $454.00K 10-Q · filed 2019-08-09 |
| 2019-03-31 | $485.00K 10-Q · filed 2019-05-09 |
| 2018-12-31 | $460.00K 10-K · filed 2020-03-11 |
| 2018-09-30 | $523.00K 10-Q · filed 2018-11-08 |
| 2018-06-30 | $631.00K 10-Q · filed 2018-08-08 |
| 2018-03-31 | $440.00K 10-Q · filed 2018-05-10 |
| 2017-12-31 | $395.00K 10-K · filed 2019-03-08 |
| 2017-09-30 | $187.00K 10-Q · filed 2017-11-09 |
| 2017-06-30 | $190.00K 10-Q · filed 2017-08-09 |
| 2017-03-31 | $180.00K 10-Q · filed 2017-05-10 |
| 2016-12-31 | $205.00K 10-K · filed 2018-03-16 |
| 2016-09-30 | $190.00K 10-Q · filed 2016-11-09 |
| 2016-06-30 | $232.00K 10-Q · filed 2016-08-09 |
| 2016-03-31 | $181.00K 10-Q · filed 2016-05-10 |
| 2015-12-31 | $190.00K 10-K · filed 2017-03-14 |
| 2015-09-30 | $776.00K 10-Q · filed 2015-11-06 |
| 2015-06-30 | $768.00K 10-Q · filed 2015-08-10 |
| 2015-03-31 | $812.00K 10-Q · filed 2015-05-11 |
| 2014-12-31 | $849.00K 10-K · filed 2016-03-14 |
| 2014-09-30 | $860.00K 10-Q · filed 2014-11-06 |
| 2014-06-30 | $663.00K 10-Q · filed 2014-08-07 |
| 2014-03-31 | $1.10M 10-Q · filed 2014-05-08 |
| 2013-12-31 | $1.09M 10-K · filed 2015-03-13 |
| 2013-09-30 | $1.01M 10-Q · filed 2013-11-08 |
| 2013-06-30 | $671.00K 10-Q · filed 2013-08-09 |
| 2013-03-31 | $636.00K 10-Q · filed 2013-05-09 |
| 2012-12-31 | $631.00K 10-K · filed 2014-03-17 |
| 2012-09-30 | $607.00K 10-Q · filed 2012-11-06 |
| 2012-06-30 | $692.00K 10-Q · filed 2012-08-03 |
| 2012-03-31 | $630.00K 10-Q · filed 2012-05-08 |
| 2011-12-31 | $647.00K 10-K · filed 2013-03-07 |
| 2011-09-30 | $686.00K 10-Q · filed 2011-11-08 |
| 2011-06-30 | $730.00K 10-Q · filed 2011-08-05 |
| 2010-12-31 | $918.00K 10-K · filed 2012-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |